Our top pick for
Asensus Surgical Inc is a medical devices business based in the US. Asensus Surgical shares (TRXC) are listed on the NYSE MKT and all prices are listed in US Dollars. Asensus Surgical employs 160 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$0.35 - $6.88|
|50-day moving average||$4.29|
|200-day moving average||$1.62|
|Wall St. target price||$1.45|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.34|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$2.8 million|
|Gross profit TTM||$-4,792,000|
|Return on assets TTM||-44.58%|
|Return on equity TTM||-94.1%|
|Market capitalisation||$916.9 million|
TTM: trailing 12 months
There are currently 6.7 million Asensus Surgical shares held short by investors – that's known as Asensus Surgical's "short interest". This figure is 26.9% down from 9.2 million last month.
There are a few different ways that this level of interest in shorting Asensus Surgical shares can be evaluated.
Asensus Surgical's "short interest ratio" (SIR) is the quantity of Asensus Surgical shares currently shorted divided by the average quantity of Asensus Surgical shares traded daily (recently around 48.2 million). Asensus Surgical's SIR currently stands at 0.14. In other words for every 100,000 Asensus Surgical shares traded daily on the market, roughly 140 shares are currently held short.
However Asensus Surgical's short interest can also be evaluated against the total number of Asensus Surgical shares, or, against the total number of tradable Asensus Surgical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Asensus Surgical's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Asensus Surgical shares in existence, roughly 30 shares are currently held short) or 0.0302% of the tradable shares (for every 100,000 tradable Asensus Surgical shares, roughly 30 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Asensus Surgical.
Find out more about how you can short Asensus Surgical stock.
We're not expecting Asensus Surgical to pay a dividend over the next 12 months.
Asensus Surgical's shares were split on a 1:13 basis on 11 December 2019. So if you had owned 13 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Asensus Surgical shares – just the quantity. However, indirectly, the new 1200% higher share price could have impacted the market appetite for Asensus Surgical shares which in turn could have impacted Asensus Surgical's share price.
Over the last 12 months, Asensus Surgical's shares have ranged in value from as little as $0.3515 up to $6.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Asensus Surgical's is 1.9772. This would suggest that Asensus Surgical's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Asensus Surgical, Inc. engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. It digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through a new category of care called Digital Laparoscopy. The company's digital interface enables the use of capabilities, such as augmented intelligence, connectivity, and robotics in laparoscopy, as well as allows to address the current clinical, cognitive, and economic shortcomings in surgery. The company's products include Senhance Surgical System, a multi-port robotic surgery system that allows multiple robotic arms to control instruments and a camera; and SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform. It offers its products directly and through distributors in Europe, the United States, Japan, Taiwan, and internationally. The company was formerly known as TransEnterix, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.